Emel Yilmaz

Prof. Emel Yilmaz


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Journal of Medical Mycology
Verified
Journal Article
Closed access
EKEsra Kazak
Esra Kazak
EAE. Aslan
E. Aslan
EAEMİN HALİS Akalin
EMİN HALİS Akalin
ÖSÖ. Saraydaroğlu
Ö. Saraydaroğlu
BHB. Hakyemez
B. Hakyemez
SHS. Helvacı
S. Helvacı

4 November 2015 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
SŞSeniha Şenbayrak
Seniha Şenbayrak
NONuri Ozkutuk
Nuri Ozkutuk
HEHakan Erdem
Hakan Erdem
IJIsik Somuncu Johansen
Isik Somuncu Johansen
Rok ČivljakRok Čivljak
Rok Čivljak
HVHaluk Vahaboglu
Haluk Vahaboglu
Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any first-line drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38–6.82) and 2.14 (95 % CI, 0:34–13:42), respectively. INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing.

26 June 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
NTNazmiye Ülkü Tüzemen
Nazmiye Ülkü Tüzemen
UOUgur Onal
Ugur Onal
EKEsra Kazak
Esra Kazak
NTNergiz Tezgeç
Nergiz Tezgeç
HEHale Eren
Hale Eren
CÖCüneyt Özakın
Cüneyt Özakın

8 January 2010 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
EGE. Gürcüoğlu
E. Gürcüoğlu
BEBeyza Ener
Beyza Ener
EAEMİN HALİS Akalin
EMİN HALİS Akalin
MSM. Sinirtaş
M. Sinirtaş
CEC. Evci
C. Evci
YHY. Heper
Y. Heper
SUMMARY: The incidence of nosocomial candidaemia was evaluated in a retrospective study in a Turkish tertiary-care hospital. Over a 12-year period (1996–2007), a total of 743 episodes of candidaemia occurred in 743 patients, accounting for an average incidence of 1·9 episodes/1000 admissions and 2·9 episodes/10 000 patient-days per year. The annual incidence was almost constant during the study period except for 1996 when it was significantly higher in comparison with other years (P<0·05). The most common species isolated was Candida albicans (45%), followed by C. parapsilosis (26%), C. tropicalis (7%), C. krusei (7%), and C. glabrata (3·5%). A significant increase in C. albicans isolates causing candidaemia linked to a decrease in C. parapsilosis isolates in adult patients and C. krusei isolates in children was found between the two 6-year study periods. This trend reflects improved infection control at Uludağ University Hospital. Ninety percent of isolates were susceptible to fluconazole (⩽8 μg/ml) and resistance was found only in C. glabrata and C. parapsilosis isolates. Regular local surveillance of Candida spp. is important in order to develop empirical treatment protocols to reduce the incidence and mortality of candidaemia.

14 May 2025 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
CSCihan Semet
Cihan Semet
EKEsra Kazak
Esra Kazak
BEBeyza Ener
Beyza Ener
SASecil AK-AKSOY
Secil AK-AKSOY
GOGuven Ozkaya
Guven Ozkaya
EAEMİN HALİS Akalin
EMİN HALİS Akalin
Candidemia ranks among the top causes of nosocomial bloodstream infections, significantly increasing hospital stays and costs. Rapid and effective empirical antifungal therapy is crucial. The Candida parapsilosis species complex, the second most common cause of candidemia, has shown rising fluconazole resistance globally and in our country. Additionally, echinocandins exhibit higher minimum inhibitory concentrations (MICs) for C. parapsilosis, complicating empirical treatment decisions. This retrospective study analyzed 173 C. parapsilosis candidemia cases over 22 years in a tertiary care hospital. We compared 88 fluconazole non-susceptible (minimum inhibitory concentration [MIC] = 4 µg/mL: susceptible dose dependent; MIC ≥ 8 µg/ml resistant) and 85 fluconazole susceptible cases, examining demographics, clinical characteristics, risk factors, and 28-day mortality. Independent risk factors for fluconazole non-susceptibilty included age ≥ 66 years (p = 0.016), central venous catheter use (p < 0.001), total parenteral nutrition (p = 0.003), and colostomy (p = 0.049). Fluconazole non-susceptible cases had lower microbiological cure rates and higher mortality. Mortality in this group was independently associated with microbiological cure failure (p < 0.001). This study highlights the importance of identifying risk factors to estimate the likelihood of resistant pathogens, initiating targeted antifungal therapy, and providing individualized management. Monitoring local resistance patterns is essential to guide empirical therapy. Further multicenter research is needed to validate findings and optimize treatment for fluconazole resistant candidemia. Clinical trial number: Not applicable.

20 October 2021 in Cureus
Verified
Journal Article
Open access
TTTekin Tuncel
Tekin Tuncel
EAEMİN HALİS Akalin
EMİN HALİS Akalin
MPMelda Payaslıoğlu
Melda Payaslıoğlu
EYEmel Yilmaz
Emel Yilmaz
EKEsra Kazak
Esra Kazak
CÖCüneyt Özakın
Cüneyt Özakın
Stenotrophomonas maltophilia (SM) is one of the common gram-negative pathogens that cause nosocomial infections. The aim of the present study is to evaluate the treatment and outcome of SM bacteraemia. We retrospectively evaluated antimicrobial treatment in adult patients with nosocomial SM bacteraemia, with the 14th and 30th-day mortality as the outcome. In total, 140 adult patients with SM bacteraemia who were diagnosed between January 1, 2002, and December 31, 2016 were enrolled in the present study. Seventy-one (50.7%) patients were in the intensive care unit (ICU). The 14th and the 30th-day mortality rates were 32.9% (n=46) and 45.7% (n=64), respectively. Female sex (OR, 7.47; 95% CI 1.61-34.47, p<0.01), steroid use within the last month (OR, 10.2; 95% CI 1.27-82.27, p=0.029), Pittsburgh bacteraemia score (PBS) ≥4 (OR, 39.9; 95% CI 4.96-321.32, p<0.001) and solid organ malignancy (OR, 9.6; 95% CI 1.73-53.72, p<0.01) were independent risk factors for 14th day mortality. Removal of the catheter was an independent protective factor for both 14th (OR, 0.05; 95% CI 0.22-0.010, p<0.001) and 30th day (OR, 0.039;95% CI 0.164-0.009, p<0.001) mortality. We did not detect any difference between treatment regimens including trimethoprim-sulfamethoxazole (TMP/SMX) or levofloxacin in terms of mortality. We found that TMP/SMX and levofloxacin combination did not significantly improve patient prognosis. Due to the high mortality rates associated with nosocomial SM bacteraemia, adequate antibiotic therapy should be initiated immediately in the suspicion of infection, and prompt removal of any indwelling central venous catheter is important.